豪赌“超级流感药”!默沙东缘何92亿美元收购Cidara?

21世纪经济报道
Yesterday

面对王牌抗癌药Keytruda(帕博利珠单抗)即将面临的专利悬崖危机,默沙东(MSD)斥资92亿美元,收购Cidara公司的创新流感药物CD388——这款在二期临床试验中预防效力高达76%的潜在“超级流感药”。  近日,默沙东与Cidara Therapeutics共同宣布,双方已签署最终协议,根据该协议,默沙东将以约92亿美元的总额收购Cidara。这一消息发布后,位于圣地亚哥的生物技术公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10